Dr. Bekaii-Saab on the Potential Impact of Napabucasin Combo in Pancreatic Cancer

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the potential impact of the combination of napabucasin with gemcitabine and nab-paclitaxel in pancreatic cancer.

Bekaii-Saab says the big takeaways from the phase II study of napabucasin with gemcitabine and nab-paclitaxel is that it is a safe regimen, and given the lack of standard of care in pancreatic cancer, this is an opportunity to improve upon the activity of an established regimen.